Skip to main
MDXH

MDxHealth SA (MDXH) Stock Forecast & Price Target

MDxHealth SA (MDXH) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MDxHealth is a leading multinational healthcare company that offers molecular diagnostic tests and services to personalize cancer diagnosis and treatment. With a strong focus on urologic cancers, the company's proprietary genomic, epigenetic, and other molecular technologies provide physicians with actionable information to improve patient outcomes. Despite a recent setback with its Resolve UTI test, the company is poised for long-term growth with a portfolio of top-performing tests recommended under NCCN guidelines. Its recent acquisition of Exosome Diagnostics further strengthens its position in the urology market and presents potential cost-savings to the U.S. healthcare system. With a path to positive free cash flow and a disciplined approach to potential growth opportunities, MDxHealth is well-positioned for success.

Bears say

MDxHealth is facing several challenges that have led to a negative outlook on the stock. These challenges include the discontinuation of its Resolve UTI test due to a CMS matter, a Q1 miss and lowered guidance, and the company's unwillingness to pursue alternative billing strategies. Despite its recent acquisition of the ExoDx test and expected growth from its Oncotype DX prostate cancer test, MDxHealth's fundamentals remain weak, with missed revenue and EBITDA estimates for Q1. Additionally, the company's lack of transparency regarding specific tests and declining tissue volume add to the uncertainty of its future performance.

MDxHealth SA (MDXH) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MDxHealth SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MDxHealth SA (MDXH) Forecast

Analysts have given MDxHealth SA (MDXH) a Strong Buy based on their latest research and market trends.

According to 3 analysts, MDxHealth SA (MDXH) has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MDxHealth SA (MDXH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.